The authors suggest that a positive feedback loop involving sSema4D/IL-6 and TNFα/ADAMTS-4 participates in RA pathogenesis and that anti-Sema4D Ab or other specifically Sema4D targeting strategies could be therapeutically beneficial for RA patients. Here, TNF is linked to rheumatoid arthritis.